STAT+: From Revolution Medicines, more strong data on KRAS drug and a glimpse of a ‘novel class’ beyond it

Summary: At a major cancer research meeting in San Diego, a company called Revolution Medicines is the talk of the town. They shared exciting new results for a drug called daraxonrasib, which is showing great promise in treating advanced pancreatic cancer. But the biggest surprise came from the company's CEO, Mark Goldsmith. He revealed early research on a brand-new type of drug known as RM-055. Instead of just blocking the signals that cause cancer to grow, this new "catalytic inhibitor" acts like a switch to completely turn the cancer protein off. It is a huge step forward in the fight against the disease.

For more details, see statnews at statnews.com/2026/04/21/aacr-2026-pancreatic-cancer-revolution-medicines-future/?utm_campaign=rss (opens in new tab)